The T Lymphocyte Activation Antigen CD80 pipeline drugs market research report outlays comprehensive information on the T Lymphocyte Activation Antigen CD80 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the T Lymphocyte Activation Antigen CD80 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, Immunology, Metabolic Disorders, and Central Nervous System which include the indications Solid Tumor, Gastric Cancer, Rheumatoid Arthritis, Graft Versus Host Disease (GVHD), Type 1 Diabetes (Juvenile Diabetes), Pre-Diabetes/Impaired Glucose Tolerance, Alzheimer’s Disease, and Amyotrophic Lateral Sclerosis. It also reviews key players involved in T Lymphocyte Activation Antigen CD80 targeted therapeutics development with respective active and dormant or discontinued products.
The T Lymphocyte Activation Antigen CD80 pipeline targets constitutes close to 16 molecules. Out of which, approximately 15 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, and Preclinical stages are 1, 8, 2, and 4 respectively. Similarly, the universities portfolio in Preclinical comprises 1 molecule.
T Lymphocyte Activation Antigen CD80 overview
Cluster of differentiation 80 or CD80 or B7-1 is a protein found on dendritic cells, activated B cells and monocytes. The activated protein induces T-cell proliferation and cytokine production. T-cell proliferation and cytokine production is induced by the binding of CD28.
For a complete picture of T Lymphocyte Activation Antigen CD80’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
